- Home
- FLYE vs ACXP Comparison
FLYE vs ACXP Comparison
Compare FLYE & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- ACXP
- Stock Information
- Founded
- FLYE 2018
- ACXP 2017
- Country
- FLYE United States
- ACXP United States
- Employees
- FLYE N/A
- ACXP N/A
- Industry
- FLYE Aerospace
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- ACXP Health Care
- Exchange
- FLYE Nasdaq
- ACXP Nasdaq
- Market Cap
- FLYE 10.2M
- ACXP 8.4M
- IPO Year
- FLYE 2024
- ACXP 2021
- Fundamental
- Price
- FLYE $0.92
- ACXP $0.43
- Analyst Decision
- FLYE
- ACXP Strong Buy
- Analyst Count
- FLYE 0
- ACXP 2
- Target Price
- FLYE N/A
- ACXP $10.00
- AVG Volume (30 Days)
- FLYE 883.1K
- ACXP 18.4M
- Earning Date
- FLYE 08-18-2025
- ACXP 08-08-2025
- Dividend Yield
- FLYE N/A
- ACXP N/A
- EPS Growth
- FLYE N/A
- ACXP N/A
- EPS
- FLYE N/A
- ACXP N/A
- Revenue
- FLYE $28,547,111.00
- ACXP N/A
- Revenue This Year
- FLYE N/A
- ACXP N/A
- Revenue Next Year
- FLYE N/A
- ACXP N/A
- P/E Ratio
- FLYE N/A
- ACXP N/A
- Revenue Growth
- FLYE N/A
- ACXP N/A
- 52 Week Low
- FLYE $0.33
- ACXP $0.30
- 52 Week High
- FLYE $7.30
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- ACXP 47.99
- Support Level
- FLYE N/A
- ACXP $0.52
- Resistance Level
- FLYE N/A
- ACXP $0.63
- Average True Range (ATR)
- FLYE 0.00
- ACXP 0.09
- MACD
- FLYE 0.00
- ACXP 0.00
- Stochastic Oscillator
- FLYE 0.00
- ACXP 17.33
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.